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Over the past decade, more than 12 genes have been identified to cause hereditary
predispositions to hematologic malignancies. These syndromes are characterized by an
increased risk to develop myelodysplastic syndrome (MDS), acute myeloid leukemia (AML),
or aplastic anemia (AA) at young ages, with various phenotypic features including peripheral
cytopenias, immune dysfunction and skeletal defects. In 2013, Churpek et al. proposed a
referral algorithm which consists of certain criteria for identifying leukemia patients who
may benefit from genetic assessment for these hereditary syndromes. These criteria assess
personal history of cytopenias, skin or nail abnormalities, immune deficiencies/atypical
infections, and other associated clinical characteristics. The algorithm also assesses family
history of leukemia and personal/family history of other malignancies.

Our study aimed to assess the applicability of these criteria on an unselected
population of adults with leukemia by retrospective chart review at The University of Texas
M.D. Anderson Cancer Center. These patients presented for initial consultation from March
1, 2014 to December 31, 2014. Six-hundred and eight individuals diagnosed with
MDS/AML/AA were included in this study. Key demographic information was obtained
from a clinical database maintained by the Department of Leukemia. The median age at
diagnosis was 67 years, 387 (64%) were male, and at the time of data collection, 315 (51.8%)
individuals were alive. Of the 608 individuals in this study, 334 (54.9%) were diagnosed with
AML, 199 (32.7%) with MDS, 59 (9.7%) with MDS/MPD, and 16 (2.6%) with AA.
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Regarding clinical/medical record documentation of referral criteria, three hundred
and sixty-four (59.9%) individuals reported at least one first or second-degree relative with
cancer. Thirty-one (5.1%) individuals reported a family history of leukemia, which was also
the most consistently reported criteria in the medical record (n=580, 95.4%). Overall, 406
individuals (66.8%) had insufficient documentation to determine whether any criteria were
met. Two hundred and two (33.2%) individuals met at least one of the proposed criteria for
genetic counseling referral; however, only nine received a referral (4.5%) to genetic
counseling. Increased documentation of the presence or absence of phenotypic features
associated with these hereditary syndromes is necessary to better assess the applicability of
these criteria, and to ensure that individuals receive appropriate referral for cancer genetics
risk assessment.
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Introduction
Leukemia is the tenth most common malignancy in the United States with an estimated
60,140 new cases diagnosed in 2016 [1]. Familial occurrences of leukemia have been
documented in the literature and first-degree relatives of individuals with leukemia carry an
estimated 2.5-6 fold increased lifetime risk of leukemia depending on the type of leukemia in
the family [6, 7]. In fact, approximately 10-20% of myelodysplastic syndromes (MDS), acute
myeloid leukemia (AML), and aplastic anemia (AA) are related to newly-described
hereditary predisposition syndromes [2-5].
Over the past decade, clinical investigations into families with multiple close relatives
with leukemia have identified more than a dozen genes related to inherited predispositions to
MDS and AML [3]. To date, genes associated with inherited MDS/AML syndromes include
ANKRD26, ATG2B, CEBPA, DDX41, ETV6, GATA2, GSKIP, RUNX1, SH2B3, SRP72 and
TP53. Additional predisposition genes are also related to the inherited bone marrow failure
syndromes (IBMFS), including Fanconi anemia (FA) caused by mutations in the Fanconi
complementation groups (FANCA, BRCA2, PALB2, etc.) and dyskeratosis congenita (DC)
caused by mutations in telomere maintenance genes (TERT, TERC) which have been
associated with increased risks for AA, MDS, and AML. Together, these syndromes are
characterized by significantly increased risk to develop MDS/AML/AA (30-100% lifetime
risk) at younger ages (4-40 years old on average), with phenotypic characteristics including
thrombocytopenia, other peripheral cytopenias, immune dysfunction, skeletal defects, and
clinical bleeding in both adults and children [8, 9]. Additional phenotypes include primary
lymphedema, deafness, cutaneous warts, low CD4/CD8 T cell ratio and mycobacterial
infections [10-12], which can be seen in patients with germline GATA2 mutations.

Recently, research has revealed that previously described conditions like FA and DC
have more variable phenotypic expressivity than previously described, with 25-40% of
individuals with FA, and 10-25% of individuals with DC, having no physical characteristics
suggestive of these conditions [13, 14]. Additionally, individuals with IBMFS who do not
show classic physical characteristics are more likely to have delayed diagnosis of
MDS/AML/AA, often in adulthood [13]. This variability makes IBMFS difficult to diagnose
in individuals who do not display the characteristic phenotype. Timely diagnosis is critical
for treatment of MDS/AML/AA, as patients with IBMFS and familial AML/MDS syndromes
have poor outcomes from hematopoietic stem cell transplantation (HSCT) due to use of a
related donor with the same germline mutation and/or increased toxicity from high-intensity
transplant conditioning regimens [15-17].
The complications arising from HSCT transplantation from a related donor illustrates
the importance of a thorough family history for these at risk individuals. In 2014, the
American Society of Clinical Oncology (ASCO) published an expert opinion statement
regarding the collection and use of family history in oncology assessments and suggested that
the minimum family history obtained should include cancer history of first- and seconddegree relatives, including the type of primary cancer and age of diagnosis [14]. Although
not all patients report an accurate family history, a study by Ziogas and Anton-Culver
showed that most patient reports of family history are reliable, especially when reporting
cancer history of first-degree relatives [18]. According to the ASCO statement, clinicians
should be able to assess a family history to help determine if further evaluation for hereditary
predisposition is warranted; however, a study by Sussner et al. revealed that only 1.7% of
surveyed physicians felt they could accurately interpret a family history and make
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appropriate recommendations [19, 20]. While previously considered exceedingly rare, the
recent discovery of multiple hematologic malignancy predisposition syndromes requires
increased clinical provider awareness. For optimal identification and appropriate referral of
patients at risk of hereditary cancer syndromes, an accurate, detailed family history is critical
to identify at-risk patients and families, as well as to help guide treatment and management.
With the identification of these predisposition genes, researchers have sought to
understand how frequently these germline mutations occur in patients with leukemia.
DiNardo et al. identified germline mutations associated with a hereditary cancer syndrome in
18% of patients with hematologic malignancies referred for genetic testing [2, 21]. Another
study by Churpek et al. in 2016 illustrated a similar frequency of germline mutations (1124%) in patients with hematologic malignancies referred for genetic testing [2]. Notably,
germline mutations in hematologic malignancies appear to show similar prevalence to
germline mutations in solid tumors such as breast and colon cancers for which genetic risk
assessment has become routine.
In 2013, Churpek et al. proposed clinical detection and management criteria for
patients and family members with familial MDS/AML/AA predisposition syndromes (Figure
1).
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Figure 1. Proposed Algorithm for identifying individuals for referral for comprehensive
cancer risk assessment
Patient with MDS/AML/ALL

Family History of:
-MDS/AML/ALL/AA
-Early onset cancers of
any type
- Multiple close
relatives with cancer

Personal or family history of:
- Low blood counts
- Bleeding diathesis
- Skin or nail abnormalities
- Unexplained liver disease
- Pulmonary fibrosis or
alveolar proteinosis
- Limb anomalies
- Lymphedema
- Immune deficiencies/
atypical infections

Yes

No

Referral for
comprehensive
cancer risk
assessment

Family history should
be updated every 5
years

These criteria assess personal or family history of cytopenias, the presence of skin,
nail, or limb abnormalities, unexplained liver disease, pulmonary fibrosis/alveolar
proteinosis, lymphedema and immune deficiencies/atypical infections. Additionally, the
algorithm assesses family history of acute lymphocytic leukemia (ALL)/MDS/AML/AA and
other malignancies. Individuals meeting these criteria warrant referral to genetic counseling
for comprehensive cancer risk assessment.
To date, no studies have sought to evaluate the clinical applicability of these criteria
to an unselected adult population of leukemia patients. We aim to assess the proposed
algorithm against a large unselected cohort of patients with MDS/AML/AA to determine if
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the characteristics needed to identify these patients for genetic counseling and risk
assessment are reported in the medical record. Identifying these individuals is of utmost
importance for personalized treatment strategies to maximize positive outcomes and
minimize toxicity.

Materials and Methods
Patient Selection
We identified 613 individuals seen as new patients in the Department of Leukemia at The
University of Texas M.D. Anderson Cancer Center between March 1, 2014 to December 31,
2014 with a diagnosis of MDS, AML, or AA. Five individuals were excluded either due to
age (<18 years old) at the time of their initial appointment, no leukemia diagnosis, or no
medical records available for review, leaving 608 individuals for analysis. Medical history
and pathology were obtained from a prospectively-maintained clinical database within the
Department of Leukemia. Personal and family history, genetic testing performed, and referral
criteria from the Churpek et al. algorithm were obtained by electronic medical record chart
review. A somatic 28-gene panel was performed for all 608 patients and this information was
used to assess for double mutant (dm) somatic mutation carriers. To ensure adequate data
capture, chart review procedure included assessment of the first five and last five leukemia
department provider’s notes, and the leukemia department providers’ history and physical
notes (H&P).
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Statistical Analyses
Patient demographics, clinicopathologic characteristics, and personal and family history
variables were analyzed. We evaluated 608 patients with MDS/AML/AA for the proposed
criteria (Figure 1) to determine if they met the proposed criteria, and whether eligible patients
were recommended for cancer genetic risk assessment. The statistical significance between
cohorts was determined using the chi-squared test and Fisher’s exact test for categorical
variables, Wilcoxon rank sum test for continuous variables and nonparametric test for trend
for ordered variables. All analyses were performed in STATA (v.13.1, College Station, TX).
P-value <0.05 was set for statistical significance. This study was approved by the
Institutional Review Board of The University of Texas M.D. Anderson Cancer Center and by
the Committee for the Protection of Human Subjects of the University of Texas Health
Science Center at Houston. A waiver of informed consent was obtained.
Results
Demographics
Clinical data and demographic information from 608 individuals diagnosed with
AML/MDS/AA seen at our institution from March 1, 2014-December 31, 2014 are described
in Table 1.
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Table 1. Patient Demographics (n=608)

Clinical Characteristics

n (%)

Median (IQR), age at diagnosis, years
Male sex
Vital status, living

67 (56-73)
387 (64)
315 (51.8)

Race/Ethnicity
White
Hispanic
Black
Unknown
Asian
Other
Leukemia Diagnosis

478 (78.6)
47 (7.7)
38 (6.3)
22 (3.6)
18 (3)
5 (0.8)

AML
MDS
MDS/MPD
AA

334 (54.9)
199 (32.7)
59 (9.7)
16 (2.7)

Personal History of Cancer
None
Prostate
Breast
Basal cell carcinoma
Lymphoma
Colon
Other

410 (67.4)
37 (6.1)
32 (5.3)
32 (5.3)
29 (4.7)
12 (2.0)
56 (9.2)

Family History of Cancer*
>1 FDR
>1 SDR)
None

304 (50%)
121 (19.9%)
183 (30.1%)

IQR: Inter Quartile Range
AML: Acute Myeloid Leukemia; MDS: Myelodysplastic syndrome; MPD: Myeloproliferative disorder;
AA: Aplastic anemia
FDR: First-degree relative; SDR: Second-degree relative
*Family history of cancer does not include family history of hematologic malignancies

The median age at diagnosis was 67 years, 387 (64%) were male, and at the time of data
collection, 315 (51.81%) individuals were still living. Four hundred and seventy-eight
(78.6%) individuals in the cohort reported their ethnicity as non-Hispanic white. The
majority of patients in our cohort had AML (n=334, 54.9%). Forty-three (7.1 %) individuals
7

had favorable MDS/AML cytogenetics, 278 (45.7%) had intermediate cytogenetics, and 174
(28.6%) had unfavorable cytogenetics. One hundred and thirteen (18.6%) individuals had
unknown cytogenetics results.
One hundred and ninety-eight (32.6%) individuals had a personal history of an
additional primary cancer diagnosis prior to their leukemia diagnosis. Breast cancer, prostate
cancer, and basal cell carcinoma of the skin were the three most common, comprising 51.1%
of total prior primary malignancies reported. For analysis of somatic mutation status, 29
(4.8%) individuals were found to have >2 somatic mutations in one of three genes known to
be associated with hereditary hematologic malignancies, CEBPA, RUNX1 and GATA2.

Criteria documentation and cancer genetics referral
We evaluated the presence, absence, or unreported status of the referral criteria
proposed by Churpek et al. among the 608 patients [Table 2].
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Table 2. Documentation of the evaluated personal and family history criteria (n=608)

Personal History Criteria
Skin/nail abnormalities
Anemia
Thrombocytopenia
Neutropenia
Limb anomalies
Pulmonary fibrosis/ alveolar proteinosis
Unexplained liver disease
Lymphedema
Immune deficiencies/atypical infections
Family History Criteria
Leukemia
Cancer
Other Cytopenias
Thrombocytopenia

Present
n (%)

Absent
n (%)

Unreported
n (%)

39 (6.4)
19 (3.1)
23 (3.8)
2 (0.3)
7 (1.2)
22 (3.6)
11 (1.8)
10 (1.6)

524 (86.2)
259 (42.6)
235 (38.7)
124 (20.4)
70 (11.5)
7 (1.2)
10 (1.7)
2 (0.3)

45 (7.4)
330 (54.3)
350 (57.5)
482 (79.3)
531 (87.3)
579 (95.2)
587 (96.5)
596 (98.1)

5 (0.8)

3 (0.5)

600 (98.7)

31 (5.1)
364 (59.9)
11 (1.8)
7 (1.2)

549 (90.3)
216 (35.5)
10 (1.6)
7 (1.2)

28 (4.6)
28 (4.6)
587 (96.6)
594 (97.6)

Personal history of blood count abnormalities had an unreported frequency ranging
from 54.3% (n=300) for anemia to 79.2% (n=482) for neutropenia. Physical characteristics
(skin/nail abnormalities, unexplained liver disease, pulmonary fibrosis/alveolar proteinosis,
limb anomalies, lymphedema, immune deficiencies/atypical infections) had the highest
unreported rate. Prior history of immune deficiencies/atypical infections was unreported for
98.7% (n=600) of individuals, while skin/nail abnormalities were usually reported (n=563,
92.6%). Only 3.5% (n=21) of individuals had documentation for family history of other
cytopenias. Similarly, only 2.4% (n=14) had family history of thrombocytopenia reported.
The criterion with the highest reported documentation was family history of leukemia, noted
in 95.4% (n=580) of individuals.
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Family history of MDS/AML/AA
Thirty-one (16.2%) individuals who met criteria reported a family history of MDS/AML/AA
or acute lymphoblastic leukemia (ALL) (Table 3).
Table 3. Family History of Leukemia (n=31)
Cancer Family History
AML
MDS
ALL
AA
Unknown leukemia

FDR (n=17)
n, %
2 (6.5)
3 (9.7)
0 (0)
1 (3.2)
11 (35.5)

SDR (n=17)
n, %
3 (9.7)
1 (3.2)
1 (3.2)
1 (3.2)
11 (35.5)

FDR, first-degree relative; SDR, second degree relative
AML: Acute Myeloid Leukemia; MDS: Myelodysplastic syndrome; MPD: Myeloproliferative disorder;
AA: Aplastic anemia

Two individuals reported 2 first-degree relatives with leukemia, and two individuals
reported 2 second-degree relatives with leukemia, totaling 34 family members with reported
hematologic malignancies in this cohort. The majority of reported family members with
leukemia did not have a specified subtype of leukemia documented. Five (16.1%) had a first
or second-degree relative with AML, four (12.9%) with MDS and two with AA (6.5%).

Comparison between individuals who met criteria and those who could not be determined
Overall, 406 (66.8%) individuals had insufficient documentation to determine whether any
criteria were met. Two hundred and two (33.2%) individuals met at least one of the proposed
criteria for genetic counseling referral. Due to insufficient documentation, no individuals
were classified as not meeting criteria [Table 4].
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Table 4. Comparison between patients who met criteria and could not be determined

Characteristics

Met Criteria (n=202)
n (%)

Could not be
Determined (n=406)
n (%)

p-value

Median (IQR) age at diagnosis, years

66 (56-73)

67 (56-73)

0.407

Male sex

126 (62.4)

261 (64.3)

0.655

Race
White/Caucasian
Unknown
Black
Asian
Middle Eastern
Diagnosis
AML
MDS
MDS/MPD
AA
Personal History of Cancer
Breast
Prostate
Lymphoma
Basal Cell Carcinoma
Other
None
Family History of Cancer
BREAST
FDR
SDR
LUNG
FDR
SDR
PROSTATE
FDR
SDR
COLON
FDR
SDR

0.475
163 (80.7)
21 (10.4)
12 (5.9)
6 (3)
0 (0)

315 (77.6)
48 (11.8)
26 (6.4)
12 (3)
5 (1.2)
0.250

100 (49.5)
76 (37.6)
20 (9.9)
6 (3)

234 (57.6)
123 (30.3)
39 (9.6)
10 (2.5)

18 (8.9)
11(5.4)
11(5.4)
10 (5.0)
27 (13.4)
125 (61.9)

14 (3.4)
26 (6.4)
18 (4.4)
22 (5.4)
41 (10.1)
285 (70.3)

0.006
0.721
0.553
1.00

30
13

39
19

0.058
0.441

25
16

35
17

0.151
0.060

24
5

27
8

0.042
0.768

18
7

19
15

0.048
1.000

IQR: Inter Quartile Range
AML: Acute Myeloid Leukemia; MDS: Myelodysplastic syndrome; MPD: Myeloproliferative disorder;
AA: Aplastic anemia
FDR: First-degree relative; SDR: Second-degree relative
*Family history of cancer does not include family history of hematologic malignancies
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There was no significant difference between patient’s age or sex at diagnosis and whether
they met criteria (p=0.407, p=0.655). Seventy-seven (38.1%) individuals who met criteria had
a prior malignancy. Prior history of breast cancer was associated with whether an individual
met criteria for cancer genetics referral (p=0.006). For our study, those who met criteria
solely based on their personal history of breast cancer were diagnosed with breast cancer
before age 45 as individuals diagnosed with breast cancer before age 45 meet National
Comprehensive Cancer Network (NCCN) guidelines for genetic risk assessment.
Five hundred and eighty (95.4%) patients had documentation of family history
information in their medical record. Three hundred and four (50%) individuals had at least
one first-degree relative (FDR) with cancer documented in their medical record. One hundred
and twenty-one individuals (19.9%) had at least one second-degree relative (SDR) with
cancer documented in their medical record [Table 1]. Individuals that had a first- and seconddegree relative with the same malignancy were included in both calculations. The most
commonly documented malignancies among FDRs were breast, lung, and prostate cancers,
comprising 41.5% of total malignancies reported among FDRs (n=180). Additionally, having
a FDR with prostate, colon, or ovarian cancer was a significant factor in whether or not an
individual met criteria (p=0.042, p=0.048, p=0.000). The most commonly reported
malignancies among SDRs were breast, lung, and colon cancers, comprising 50.9% of total
malignancies reported in SDRs (n=87).
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Referral to genetic counseling
Of the 202 individuals that met at least one criteria for a cancer genetics referral according to
the proposed algorithm, 166 (82.2%) met one criteria, 30 (14.8%) met 2, 5 (2.5%) met 3, and
only one patient (0.5%) met 4 criteria [Table 5].
Table 5. Referral criteria and subsequent referral to genetic counseling (n=202)

Referred to genetics (n=9)
Not referred to genetics (n=193)

1
4 (2.4)
162 (97.6)

Number of criteria met
2
3
4 (13.3)
1 (20)
26 (86.7)

4 (80)

4
0 (0)
1 (100)

p=0.002
Only 9 patients (4.5%) who met criteria received a referral for clinical cancer genetics risk
assessment The difference between number of criteria met and the likelihood for subsequent
genetics referral was statistically significant (p=0.002) with those meeting more criteria being
less likely to have been referred to genetics.

Additional Criteria
In addition to the criteria proposed by Churpek et al., we assessed the somatic mutation
profile within this MDS/AML/AA cohort. In our cohort, 29 (4.8%) individuals were found to
have >2 somatic mutations in three genes known to be associated with hereditary
hematologic malignancies and tested within our current myeloid malignancy panel: CEBPA,
RUNX1 and GATA2. Of 10 individuals with >2 CEBPA mutations, only four met one of the
proposed Churpek et al. criteria. One patient with biallelic GATA2 mutations met two
criteria. Of the 18 patients with >2 RUNX1 mutations, five met one of the referral criteria.
We also assessed young age at MDS/AML/AA diagnosis, specifically individuals diagnosed
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prior to age 40. In our cohort, 66 (10.85%) individuals were diagnosed ≤40 years. Of those,
only 17 (%) met at least one of the Churpek criteria.

Discussion
We reviewed the medical records of 608 individuals to evaluate the criteria proposed
by Churpek et al. to a large unselected adult leukemia population. The median age of
diagnosis for our cohort (67 years) is consistent with the median age of diagnosis of leukemia
within the general population (66 years [1]). Of note, in the two years since these individuals
presented to The University of Texas M.D. Anderson Cancer Center, only 51.8% are alive,
consistent with the poor long-term outcomes of MDS and AML in older patients, which have
a 5-year survival rate of 26.9% [1]. The high mortality rate within a short time period
illustrates the importance of prompt assessment and referral for genetic counseling and
testing in this unique cancer population. Due to the otherwise low documentation of the
majority of the referral criteria, individuals in this cohort met referral criteria based primarily
on a personal/family history of malignancies. Those with a personal history of breast cancer,
or a FDR diagnosed with prostate, colon or ovarian cancer, were more likely to meet criteria.
This is consistent with current national guidelines that recommend genetic counseling
referrals based on family history of these specific malignancies (i.e. BRCA1 and BRCA2
evaluation). While not directly related to assessing for inherited leukemia syndromes, it is
important to note that personal and family history of non-hematologic malignancies are
referenced in the Churpek algorithm and should be assessed according to the ASCO
guidelines, and followed up by appropriate cancer genetics evaluation (14).
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The criteria proposed by Churpek et al. are the only published screening criteria to
help identify individuals at increased risk for inherited leukemia predisposition syndromes.
National society guidelines, like those from the National Comprehensive Cancer Network
(NCCN), are lacking. The absence of published guidelines and the relative novelty of these
hereditary leukemia syndromes likely contributed to the poor documentation of these criteria
items in the medical record. As illustrated in Table 5, the vast majority of patients in this
cohort have multiple missing variables, including personal or family history characteristics
such as thrombocytopenia, limb anomalies and immune deficiencies/atypical infections. This
could partially be due to study design wherein information had to be stated unequivocally
(i.e. documentation of pertinent negatives) to be considered present or absent from the
medical record. Interestingly, the two most frequently reported criteria were family history of
leukemia and personal history of skin/nail abnormalities. Typically, family history and
physical exam are integral to an initial medical consultation. Additionally, physical exam
documentation is a required component of History & Physical medical record documentation
and therefore may have contributed to the increased reporting of skin/nail abnormalities.
Only 4.5% of patients who met at least one-referral criteria received a genetics
referral. The trends seen in Table 6 illustrate that as the number of criteria increased, so did
the percentage of patients referred. The lack of cancer genetics referrals, coupled with the
lack of documented personal and family history criteria makes it difficult to assess the true
applicability of the criteria.
One principal researcher reviewed all 608 charts and human error cannot be excluded
as a possible limitation of this study. Additionally, study design was a possible limitation to
this study. Only the first five and last five leukemia providers’ notes and H&Ps were
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examined for review. Some clinical documents, as well as charts from other specialties, were
not reviewed. Criteria may have been documented in those charts but not obtained for this
study. Racial demographics were skewed and not representative of the general population.
Additionally, this study was solely comprised of individuals seen at The University of Texas
M.D. Anderson Cancer Center, a tertiary referral center, and may not be representative of
patients diagnosed with leukemia across the United States. However, this did provide a large
population of individuals with MDS/AML/AA from which to analyze.
In addition to the criteria proposed by Churpek et al., we assessed the somatic
mutation profile within this MDS/AML/AA cohort. Current literature suggests that about 711% of somatic double mutant CEBPA (dmCEBPA) mutations are actually present in the
germline [22, 23]. While the exact frequency of somatic RUNX1 mutations found to be
germline is unknown, a two hit hypothesis for RUNX1 mutations has been proposed that
could lead to the development of acute leukemia [24]. This is important considering 6
individuals in this study with biallelic CEBPA mutations met no additional testing criteria,
but have an increased risk for an inherited susceptibility. Based on previous estimates, it is
likely that at least one individual in the cohort had a germline CEBPA mutation. We propose
that considering ≥2 somatic mutations in CEBPA, RUNX1 and GATA2 as an additional
referral criterion may be warranted, as it would potentially increase the detection of
individuals who otherwise have no additional indications for genetic risk assessment.
Additionally, the presence of a variant allele frequency suggestive of germline inheritance
(~50%) is an important question for future analysis regarding identifying patients at risk for
germline mutations. We also assessed young age at MDS/AML/AA diagnosis, specifically
individuals diagnosed prior to age 40 since individuals with IBMFS are at a significantly
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increased risk to develop BMF before the age of 40 [16]. We propose that age dx <40 and/or
the presence of >2 somatic mutations should be considered as additional criteria when
assessing leukemia patients for referral for cancer genetics risk assessment.
Suggestions to increase documentation include incorporating criteria assessment into
the EMR, or obtaining information directly from patients via a short intake
form/questionnaire. Further studies need to assess the applicability of these criteria and may
benefit from including suggested additional criteria like molecular testing results and age of
diagnosis prior to age 40. Further studies are needed to determine which combination of
criteria yields the highest association with subsequent positive germline testing results.
National guidelines for referral criteria for inherited leukemia susceptibility syndromes
would likely increase detection of families with hereditary predispositions to hematologic
malignancies.

Conclusion
One-third of individuals met at least one criteria for a cancer genetics referral based
on the proposed algorithm, while the remainder could not be determined based on
insufficient information present in the medical record. Ultimately, only nine individuals
presenting during this nine-month interval meeting criteria received genetic counseling
referrals. The presence or absence of proposed criteria must be documented in the medical
record in order to assess clinical applicability in the leukemia population. Increased and
timely detection of these families is important, as it would allow for more tailored transplant
donor selection, treatment, anticipatory guidance counseling, and increased screening for at
risk family members.
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